Medical AI technology company Elucid has begun site recruitment for its Plaque as a Risk Factor for Evaluation of Vascular Events (PRE-VUE) CT registry study.
PRE-VUE is an international, multicenter, retrospective trial that will evaluate the prognostic accuracy of the company’s PlaqueIQTM software, a plaque-based FFRCT application for predicting major cardiac adverse events (MACE) in patients who have received clinically indicated coronary CT angiography (CCTA). The study will include at least 30 centers and a pool of at least 10,000 patients over 18 years of age who have undergone baseline CCTA with continuous follow-up for a minimum of 36 months.
Lead investigators for the study are Carlo De Cecco, MD, PhD, of Emory University in Atlanta, and Márton Kolossváry, MD, PhD, of Gottsegen National Cardiovascular Center in Budapest, Hungary.
